ONCIMMUNE HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.35 GBX | 0.00% |
|
-10.31% | -43.06% |
| 21/05 | EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss | AN |
| 21/05 | Earnings Flash (ONC.L) ONCIMMUNE HOLDINGS Posts Fiscal H1 Revenue GBP1.2M | MT |
| Sales 2024 * | 28.22L 35.79L 30Cr | Sales 2025 * | 69.15L 87.7L 73Cr | Capitalization | 1.06Cr 1.35Cr 112.66Cr |
|---|---|---|---|---|---|
| Net income 2024 * | -20L -25.36L -21Cr | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 5.33 x |
| Net Debt 2024 * | 44L 55.8L 47Cr | Net Debt 2025 * | 26L 32.97L 28Cr | EV / Sales 2025 * | 1.91 x |
| P/E ratio 2024 * |
-3.99
x | P/E ratio 2025 * |
19.4
x | Employees | 52 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -10.31% | ||
| Current month | -27.16% | ||
| 1 month | -41.43% | ||
| 3 months | -14.58% | ||
| 6 months | -47.05% | ||
| Current year | -43.06% |
1 week
13.70
16.90
1 month
13.7026.00
Current year
13.7031.00
1 year
13.0031.00
3 years
13.00210.00
5 years
13.00261.63
10 years
13.00261.63
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 01/23/01 | |
Martin Hudson
DFI | Director of Finance/CFO | - | 04/23/04 |
James R. Jett
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Goold
BRD | Director/Board Member | 52 | 13/23/13 |
Timothy Bunting
BRD | Director/Board Member | 61 | 09/15/09 |
Ron Kirschner
COO | Chief Operating Officer | - | 20/20/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 14.35 | 0.00% | 33,350 |
| 13/24/13 | 14.35 | -7.12% | 123,321 |
| 12/24/12 | 15.45 | -1.59% | 7,435 |
| 11/24/11 | 15.7 | -1.88% | 1,395 |
| 10/24/10 | 16 | 0.00% | 26,861 |
Delayed Quote London S.E., June 14, 2024 at 09:05 pm IST
More quotes
Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.
Sector
Pharmaceuticals
Calendar
27/02/2025
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.06% | 1.35Cr | |
| +19.36% | 8TCr | |
| +15.93% | 924.76Cr | |
| +42.06% | 444.73Cr | |
| -22.01% | 443.09Cr | |
| +8.28% | 402.94Cr | |
| +11.22% | 224.47Cr | |
| -26.61% | 218.19Cr | |
| +11.64% | 202.03Cr | |
| -42.69% | 179.07Cr |
- Stock Market
- Equities
- ONC Stock
